XUE Chong-xiang, ZHANG Xu, LU Xing-yu, CUI Hui-juan

1. Beijing University of Chinese Medicine, Beijing 100029, China

2. Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China

ARTICLE INFO

Article history:

Received 5 Oct 2023

Received in revised form 8 Dec 2023

Accepted 16 Jan 2024

Available online 28 Feb 2024

Keywords:

Non-small cell lung cancer

CtDNA

Targeted therapy

Concomitant mutations

Research progress

ABSTRACT Owing to significantly prolonged survival, targeted therapy has become standardized recommendation for advanced non-small cell lung cancer patients with mutated driver genes.However, the genetic status of lung cancer patients is dynamic.By dynamically monitoring the evolution of genes status, differential genes and concomitant genes related to progressive disease could be confirmed early, so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients.Under the guidance of accurate genetic testing results, it is helpful to provide patients with more effective,long-term, and stable individualized targeted therapy.